S1PR2: A Potential Drug Target Or Biomarker for Cancer and Neurodegenerative Diseases

Target Name: S1PR2

NCBI ID: G9294

S1PR2

S1PR2: A Potential Drug Target Or Biomarker for Cancer and Neurodegenerative Diseases

S1PR2 (CTD-2369P2.2) is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the S1P family of transmembrane proteins, which are known for their involvement in various cellular processes, including signaling and cell-cell adhesion. S1PR2 has been shown to play a role in the regulation of inflammation, immune cell function, and tissue repair.

Recent studies have suggested that S1PR2 may be a drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because S1PR2 has been shown to be involved in the development and progression of these conditions, and may be a useful target for therapeutic intervention.

One potential mechanism by which S1PR2 may be involved in the development of cancer is its role in cell signaling. S1PR2 has been shown to play a negative role in the regulation of cell proliferation and survival, and may be involved in the inhibition of cancer cells Growth and survival. This is consistent with the idea that S1PR2 may be a potential drug target for cancer therapies that target cell signaling pathways.

Another potential mechanism by which S1PR2 may be involved in the development of neurodegenerative diseases is its role in the regulation of inflammation and immune cell function. S1PR2 has been shown to play a role in the regulation of immune cell function, including the regulation of T cell activity and the production of antibodies. This is consistent with the idea that S1PR2 may be involved in the development of neurodegenerative diseases, such as Alzheimer's disease, by contributing to the immune system's response to the disease.

In addition to its potential role in the regulation of cancer and neurodegenerative diseases, S1PR2 has also been suggested as a potential biomarker for these conditions. This is because its expression has been shown to be altered in various tissues and conditions that are associated with the development of these diseases, including cancer and neurodegenerative diseases. This suggests that S1PR2 may be a useful biomarker for the diagnosis and assessment of these conditions.

Overall, S1PR2 is a protein that has been shown to play a role in various cellular processes throughout the body, including the regulation of cell signaling, inflammation, and immune cell function. Its potential as a drug target or biomarker for various diseases makes it an attractive target for further research and therapeutic intervention. Further studies are needed to fully understand its role in these processes and its potential as a therapeutic intervention.

Protein Name: Sphingosine-1-phosphate Receptor 2

Functions: Receptor for the lysosphingolipid sphingosine 1-phosphate (S1P) (PubMed:10617617). S1P is a bioactive lysophospholipid that elicits diverse physiological effects on most types of cells and tissues (PubMed:10617617). When expressed in rat HTC4 hepatoma cells, is capable of mediating S1P-induced cell proliferation and suppression of apoptosis (PubMed:10617617). Receptor for the chemokine-like protein FAM19A5 (PubMed:29453251). Mediates the inhibitory effect of FAM19A5 on vascular smooth muscle cell proliferation and migration (By similarity)

The "S1PR2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about S1PR2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets